LZTR1

Across TCGA pan-cancer cohorts, LZTR1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LZTR1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LZTR1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LZTR1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where LZTR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LZTR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.303	<.001	11	view →
LUAD	All	II,III,IV	−0.188	<.001	9	view →
PDAC	All	All	+0.322	<.001	5	view →
LSCC	All	All	−0.058	.030	2	view →
COAD	Female	IV	−0.535	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LZTR1–HNSC

Open the HNSC breakdown →